China NMPA Drug Inspection - Xiaogan Renai Hospital - Cornus officinalis

This Hubei Province Drug Quality Bulletin, published in July 2016 and covering the first quarter of that year, details extensive quality control failures across numerous pharmaceutical entities. The regulatory body, Hubei Provincial Food and Drug Administration, conducted sampling inspections throughout the province, identifying 185 batches of non-compliant drugs. The issues spanned both Chinese Medicinal Herbs (Processed Pieces) and various customized dosage forms. For herbal products, violations included incorrect physical properties, identification discrepancies (e.g., microscopic characteristics, thin-layer chromatography), excessive moisture, impurities, ash content, and insufficient active compound levels. A significant concern was the prevalence of products either not manufactured by the indicated company, from companies with cancelled licenses, or from untraceable sources. Finished drug products, such as capsules, injections, and tablets, demonstrated issues including improper moisture levels, color variations in solutions, unacceptable impurity profiles, and deviations in dosage or weight. The regulatory framework cited for these non-compliances primarily includes the Chinese Pharmacopoeia 2010 Edition and various supplementary national and provincial drug standards. In response, local food and drug administration departments are mandated to investigate and enforce compliance, increase follow-up inspections, trace the origins of substandard or counterfeit drugs, and refer any suspected criminal activities to law enforcement. This bulletin underscores a critical need for enhanced quality assurance and supply chain integrity within the regional pharmaceutical sector.